Healthcare professionals
On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events. You can contribute to the Agency’s work by responding to public consultations. Learn more about how Healthcare Professionals are actively involved in the work of the Agency.
Featured information
-
List item
From lab to patient: journey of a medicine
EMA's new interactive timeline illustrates the journey of a medicine for human use assessed by EMA. It explains all stages from initial research to patient access, including how EMA supports medicine development, assesses the benefits and risks and monitors the safety of medicines. This initiative aims to improve understanding of how EMA works.
-
List item
Human medicines: highlights of 2019
EMA has published an overview of its key recommendations in 2019 on the authorisation and safety monitoring of medicines for human use. In 2019, EMA recommended 66 medicines for marketing authorisation. The infographic includes a selection of medicines that represent significant progress in their therapeutic areas. Once a medicine is authorised by the European Commission and prescribed to patients, EMA and the EU Member States continuously monitor its quality and benefit-risk balance and take regulatory action when needed.
-
List item
Responsible use of antibiotics: What’s your role?
To mark European Antibiotic Awareness Day on 18 November 2019, EMA has launched a social media campaign to highlight the importance of using antibiotics responsibly. The campaign includes visuals describing what ‘responsible use’ means for healthcare professionals.
-
List item
Collaboration with general practitioners
EMA and the two major organisations representing general practitioners (GPs) and family physicians in Europe have signed a joint statement committing to strengthening interactions. It contains an action plan until 2020, which includes involving GPs and family physicians in EMA evaluations, developing relevant communication activities and exploring further collaboration with research networks in primary care, with a focus on generating real-world evidence. It also identifies opportunities for cooperation in regulatory science training.
-
List item
Preventing Brexit-related medicine shortages
EMA has published a questions-and-answers document to address potential questions from stakeholders on the supply of medicines in the EU after Brexit and what the Agency, the European Commission and national competent authorities in the Member States are doing to prevent potential medicine supply shortages due to Brexit.
-
List item
Electronic product information
The European Commission, the Heads of Medicines Agencies and EMA are working together to facilitate the development of electronic tools to improve access of patients and healthcare professionals to product information in the EU. Following a stakeholder workshop, they launched a public consultation until 31 July 2019 on draft key principles to form the basis on which electronic product information (ePI) for human medicines will be developed and used in the EU.
